Your browser is no longer supported. Please, upgrade your browser.
Settings
FBIO [NASD]
Fortress Biotech, Inc.
Index- P/E- EPS (ttm)-0.57 Insider Own0.70% Shs Outstand80.85M Perf Week-0.65%
Market Cap305.51M Forward P/E48.57 EPS next Y0.06 Insider Trans-4.12% Shs Float67.64M Perf Month-16.16%
Income-43.00M PEG- EPS next Q-0.12 Inst Own32.30% Short Float1.80% Perf Quarter-28.34%
Sales44.30M P/S6.90 EPS this Y11.50% Inst Trans-0.01% Short Ratio1.69 Perf Half Y-13.56%
Book/sh1.31 P/B2.34 EPS next Y112.00% ROA-13.40% Target Price- Perf Year3.03%
Cash/sh- P/C- EPS next 5Y25.50% ROE-47.30% 52W Range2.12 - 6.10 Perf YTD-3.47%
Dividend- P/FCF- EPS past 5Y12.20% ROI-57.40% 52W High-49.84% Beta2.46
Dividend %- Quick Ratio5.90 Sales past 5Y121.10% Gross Margin66.80% 52W Low44.34% ATR0.15
Employees111 Current Ratio5.90 Sales Q/Q-10.10% Oper. Margin- RSI (14)33.82 Volatility4.87% 4.16%
OptionableYes Debt/Eq0.70 EPS Q/Q44.00% Profit Margin-97.10% Rel Volume0.43 Prev Close3.15
ShortableYes LT Debt/Eq0.64 Earnings- Payout- Avg Volume720.37K Price3.06
Recom2.00 SMA20-10.34% SMA50-16.27% SMA200-13.22% Volume307,157 Change-2.86%
Oct-02-20Initiated The Benchmark Company Buy $9
Dec-18-19Initiated B. Riley FBR Buy $9
Feb-28-18Initiated B. Riley FBR, Inc. Buy $10
Jul-11-17Initiated Rodman & Renshaw Buy $11
Mar-22-17Initiated JMP Securities Mkt Outperform
Oct-03-16Initiated ROTH Capital Buy $9
Jul-15-21 03:06AM  
Jul-08-21 08:30AM  
Jun-30-21 11:29AM  
08:00AM  
Jun-28-21 01:04PM  
Jun-17-21 08:00AM  
Jun-16-21 08:30AM  
Jun-14-21 12:27PM  
07:00AM  
Jun-11-21 06:30AM  
Jun-07-21 08:00AM  
Jun-03-21 08:00AM  
Jun-01-21 08:30AM  
May-27-21 07:15PM  
May-19-21 08:00AM  
May-18-21 08:00AM  
May-17-21 07:00AM  
May-16-21 04:00PM  
04:31AM  
May-14-21 04:30PM  
May-13-21 09:26PM  
May-12-21 12:45PM  
08:00AM  
May-10-21 07:30AM  
06:30AM  
May-07-21 09:05AM  
May-06-21 04:15PM  
Apr-21-21 08:00AM  
Apr-20-21 07:05AM  
Apr-13-21 03:09PM  
06:30AM  
Apr-12-21 08:42AM  
06:20AM  
Apr-08-21 10:14AM  
Apr-07-21 08:30AM  
Apr-05-21 07:00AM  
Apr-01-21 09:02AM  
07:00AM  
Mar-31-21 04:15PM  
Mar-30-21 07:25AM  
Mar-24-21 04:30PM  
Mar-22-21 09:00AM  
Mar-17-21 03:26AM  
Mar-09-21 04:30PM  
08:15AM  
Mar-08-21 12:30PM  
Mar-04-21 08:00AM  
08:00AM  
08:00AM  
Mar-01-21 04:11PM  
08:30AM  
08:00AM  
Feb-26-21 08:00AM  
08:00AM  
Feb-24-21 09:20AM  
08:00AM  
Feb-23-21 09:08AM  
Feb-22-21 08:00AM  
Feb-02-21 07:30AM  
Jan-26-21 03:22PM  
11:00AM  
08:20AM  
Jan-25-21 12:30PM  
11:30AM  
10:00AM  
09:00AM  
08:54AM  
12:40AM  
Jan-24-21 01:00PM  
Jan-23-21 04:00PM  
03:15PM  
Jan-22-21 12:15PM  
11:30AM  
11:00AM  
09:00AM  
Jan-21-21 12:15PM  
11:00AM  
11:00AM  
Jan-20-21 10:44PM  
09:00PM  
07:25PM  
03:00PM  
11:00AM  
11:00AM  
Jan-19-21 09:00PM  
01:00PM  
11:30AM  
11:00AM  
Jan-18-21 11:25PM  
08:30PM  
01:35PM  
11:00AM  
Jan-16-21 12:20PM  
02:58AM  
Jan-15-21 02:00PM  
Jan-14-21 11:50PM  
11:45AM  
Jan-13-21 01:30PM  
Jan-12-21 08:49PM  
12:15PM  
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rowinsky Eric KDirectorMar 02Sale4.4510,00044,500720,000Apr 09 05:25 PM
Rowinsky Eric KDirectorFeb 19Sale4.318,00034,480730,000Apr 09 05:25 PM
Rowinsky Eric KDirectorFeb 18Sale4.206,00025,200738,000Apr 09 05:25 PM
Rowinsky Eric KDirectorFeb 16Sale3.862,0007,720744,000Apr 09 05:25 PM
Rowinsky Eric KDirectorFeb 05Sale3.804,00015,200746,000Apr 09 05:25 PM
Hunter RobynChief Financial OfficerSep 22Sale4.3828,450124,611192,169Sep 25 06:37 PM
Hoenlein MalcolmDirectorAug 26Buy18.0016,667300,00616,667Sep 01 08:34 AM
ROSENWALD LINDSAY A MDPRESIDENT, CEO & CHAIRMANAug 26Buy18.0052,500945,00092,500Sep 01 08:32 AM